Overview
Metoclopramide enhances the response to acetylcholine of tissue in upper GI tract causing enhanced motility and accelerated gastric emptying without stimulating gastric, biliary, or pancreatic secretions; increases lower esophageal sphincter tone. Gimoti (metoclopramide) nasal spray is approved for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Coverage Guidelines
Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Gimoti, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member has a diagnosis of acute and recurrent diabetic gastroparesis
3. ONE of the following is met:
   a. The member has had an inadequate response or adverse reaction to metoclopramide oral tablet OR metoclopramide oral elixir
   b. The member has a contraindication to metoclopramide oral tablet OR metoclopramide oral elixir.

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition (ex. Relief of symptoms)
Limitations
1. Initial approvals and reauthorizations will be for 12 months.
2. The following quantity limits apply:
   - Gimoti 15mg/actuation (9.8mL)
   - 9.8mL (1 bottle) per 30 days

References
2. Gimoti (metoclopramide) [prescribing information]. Solana Beach, CA: Evoke Pharma Inc; June 2020.

Review History

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.